About Lifecare

We aim to complete the development, testing and introduction of the worlds first long term implantable micro sensor to give people with diabetes the modern tool they deserve for monitoring glucose levels.

Detecting glucose by the principle of the osmotic pressure holds promise of a glucose sensing technology that is suitable for both miniaturization and long term continuous monitoring in vivo without causing patient discomfort or reducing quality of life. It also offers several major advantages compared to current blood glucose measurement technologies.

The company

Our headquarter is located in Bergen, Norway. The research and development is performed through our research partner across Europe.

Lifecare AS (Ltd.) is listed on Oslo Stock Exchange (LIFE-ME), and has been dedicated to the research and development of medical sensors for health monitoring since 06/07.

The project

The Sencell-technology is protected by patents owned by Lifecare AS (LIFE-ME). These patents are granted until year 2030 and new patents are pending.

Proof of concept of the proprietary osmotic pressure sensing technology has been successfully performed in two preclinical trials 2016 – 2017, proving that the pressure technology is able to track interstitial glucose and providing stable references.

Further miniaturization of the injectable glucose sensor highlights the planned device evolution and the accuracy of the employed 3D nanosensor technology measurement system. Data shows that the Sencell technology probably employs the smallest MEMS based pressure sensor in the world, with a reliable reproducibility of measurement results and a pressure resolution, which should lead to a resolution of glucose differences higher than CGM-devices currently on the market.

Lifecare is now continuing the development of a wireless sensor prototype suitable for first long term human clinical.

Management

  • Member of the Lifecare BoD from 2011 to 2020
  • Previously held senior management, operational and director positions in several internationally active companies.
  • Chairman of Osmotex AG, Switzerland
  • Experienced leading R&D companies to the commercial stage.
  • Licensed as Attorney at law in Norway
Prof. Dr. med. Dr. rer. nat. Andreas Pfützner
CSO
  • Managing Director of PFÜTZNER Science & Health Institute GmbH, Diabetes Center & Practice, Mainz/Germany, since 2013
  • Honorary Professor of Applied Clinical Research for the University of Applied Sciences, Bingen/Germany, since 2007
  • Over 25 years of pharmaceutical and device development experience
Dr. rer. nat. Frank Flacke
VP R&D
  • International operating consultant for drug and device development, strategy as well as clinical and medical affairs in the medtech and pharma business.
  • Previously global Medical Director Devices in the diabetes division at Sanofi
  • Held management positions in several biotech and technology companies.
  • Over 20 years of experience in the pharma and medtech business
Dr. Konstantin Kloppstech
VP Technology
  • CEO of DEVmedical UG, Oldenburg Germany
  • Senior Consultant Sensor Solutions
  • Head of Technology for MEMS/NEMS Sensor Development for Medical and Industrial Sensor Solutions 2016-2019
  • PhD at the Department of Physics in Sensor Development for Fundamental Research at University of Oldenburg, Oldenburg/Germany 2011-2015
Dr. rer. nat. Sanja Ramljak
QA/QC Manager
  • Scientific Project Manager sciema UG, Mainz/Germany, since 2014
  • Post Doctoral Fellow at German Primate Centre, Göttingen/Germany, 2008 - 2010
  • PhD at the Department of Neurology, Georg-August-University, Göttingen/Germany, 2003 – 2007

Board of directors

Morten Foros Krohnstad
Chairman of the board

Kronstad is a partner in the law firm Schjødt and has extensive experience as a business lawyer with main areas of work in M&A and corporate, including corporate litigation. He serves on a number of boards as chairman and board member in Norwegian listed and un-listed companies.

Trine Teigland
Board member
  • MBA from University of St. Gallen (HSG)
  • Managed Swiss company Osmotex’ sales and marketing activities
  • Worked in Singapore for the world’s leading provider of integrated shipping services
  • BA in International Business with Chinese

Prof. Dr. Lutz Heinemann
Board member

Heinemann has a broad academic background with a special focus on research and development in insulin pharmacology and diabetes technology. Heinemann established the Profil Institute for Metabolic Research in Neuss, Germany in 2009 and since 2011 he has been Managing Editor of The Journal of Diabetes Science and Technology.

Bo Petersson
Board member

Peterson holds a Ph.D. in Chemistry from The Technical University of Denmark. Peterson has over 20 years of work experience in developing diabetes technology products, most recently as Head of Diabetes Care at Cambridge Consultants, Cambridge, UK. Petersson is today also engaged as Chief Scientific Officer in RSP Systems A / S, Copenhagen, Denmark.


Hans Johan Hekland
Board Member

Hekland has a master's degree in economics from the Norwegian School of Management (Siviløkonom -NHH). He has worked as Managing Partner in Sarsia Venture Management since 2001.

Hekland has broad expertise in fund management, strategy, business development and finance. He has extensive experience from board positions and involvement in the medical development companies and other listed and unlisted companies.

Scientific Advisory Board

Prof. David C. Klonoff
Chairman, Scientific Advisory Board
  • Clinical professor of Medicine, UCSF
  • Editor-in-chief, DST
  • Medical Director, INST
  • Chairman, i.a. DTM and ADA
  • Chaired i.e. FDA, NASA, US army, NIH, NSF
  • Consulting i.e. Sanofi, Google and Insulin
Prof. Lutz. Heinemann
Member, Scientific Advisory Board
  • Partner and Scientific Consultant, Profil
  • Co-editor, DST
  • Published 160 research articles
  • Awarded ”Leadership in Diabetes Technology”
  • Charing the EU founded project ”AP at home”
Prof. Kåre Birkeland
Member, Scientific Advisory Board
  • Professor of Internal Medicine and Endocrinology, University of Oslo
  • Senior consultant in Endocrinology, Dep. of Transplantation Medicine, Rikshospitalet, Oslo University Hospital
  • Chairman Advisory Board, Norwegian Diabetes Association
Prof. Dr. Michael Huth
Member, Scientific Advisory Board
  • Professor for experimental solid state physics
  • Stefan Lyson professor of physics
  • Member Board of Trustees Beilstein-Institut, Frankfurt am Main
  • Member Scientific Advisory Board Frankfurt Institute of Advanced Studies
  • Member Scientific Advisory Board Austrian Centre for Electron Microscopy and Nanoanalysis
  • Member Senate of the Goethe University, Frankfurt am Main
    - 170 peer-reviewed publications

Development partners

The research and development is performed through our research partner across Europe. Our partners are all rated global experts in their field.

University of Bath
England

Research at the University of Bath is improving lives and changing the world we live in.

  • Ranked 6th in the UK by the Guardian University Guide 2020

  • Awarded Gold in the Teaching Excellence Framework 2017

  • 87% of our research is classed as world-leading or internationally excellent by the most recent Research Excellence Framework 2014

Visit website

PFÜTZNER Science & Health Institute
Germany

PFÜTZNER Science & Health Institute deliver research at the highest level, incl

  • Centre for clinical studies (phases II – IV)

  • Centre for medicinal/medical product studies (incl. CE studies)

  • Laboratory studies pursuant to ISO15197:2013 for blood glucose monitoring systems

  • Performance/preference studies for medical products

  • Strategy and performance of clinical investigations

Visit website